Silco Pharmaceuticals Limited (DSE:SILCOPHL)
Bangladesh · Delayed Price · Currency is BDT 21.30
+0.50 (2.40%)
At close: Jun 16, 2026
Silco Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 408.71 | 431.54 | 410.1 | 464.7 | 559.47 | 601.06 | |
Revenue Growth (YoY) | -4.65% | 5.23% | -11.75% | -16.94% | -6.92% | -18.07% |
Cost of Revenue | 269.4 | 278.5 | 278.25 | 318.76 | 372.72 | 433.3 |
Gross Profit | 139.31 | 153.04 | 131.85 | 145.93 | 186.75 | 167.76 |
Selling, General & Admin | 62.34 | 64.82 | 62.74 | 69.74 | 80.98 | 80.09 |
Other Operating Expenses | -0 | -0 | -0 | -0 | -0 | -0 |
Operating Expenses | 72.31 | 74.78 | 72.68 | 78.75 | 89.27 | 88.37 |
Operating Income | 67 | 78.26 | 59.17 | 67.18 | 97.48 | 79.39 |
Interest Expense | -0.48 | -0.65 | -0.93 | -0.2 | -0.53 | -0.76 |
Interest & Investment Income | 0.04 | 0.04 | 0.62 | 0.4 | 0.32 | 6.12 |
Other Non Operating Income (Expenses) | 1.54 | 1.31 | 1.2 | 3.3 | 5.21 | 4.46 |
EBT Excluding Unusual Items | 68.1 | 78.96 | 60.07 | 70.69 | 102.48 | 89.21 |
Gain (Loss) on Sale of Investments | -0.93 | -0.93 | -0.72 | 18.56 | 6.48 | 0.42 |
Pretax Income | 67.17 | 78.03 | 59.35 | 89.24 | 108.96 | 89.63 |
Income Tax Expense | 32.94 | 35.38 | 13.47 | 20.02 | 24.51 | 4.98 |
Net Income | 34.23 | 42.65 | 45.88 | 69.22 | 84.45 | 84.65 |
Net Income to Common | 34.23 | 42.65 | 45.88 | 69.22 | 84.45 | 84.65 |
Net Income Growth | -26.48% | -7.04% | -33.72% | -18.03% | -0.23% | 1.77% |
Shares Outstanding (Basic) | 103 | 104 | 104 | 104 | 104 | 104 |
Shares Outstanding (Diluted) | 103 | 104 | 104 | 104 | 104 | 104 |
Shares Change (YoY) | 0.31% | - | - | - | - | - |
EPS (Basic) | 0.33 | 0.41 | 0.44 | 0.67 | 0.81 | 0.82 |
EPS (Diluted) | 0.33 | 0.41 | 0.44 | 0.67 | 0.81 | 0.82 |
EPS Growth | -26.71% | -7.04% | -33.72% | -18.03% | -0.23% | 1.77% |
Free Cash Flow | 17.21 | 7.54 | 0.05 | -1.47 | 62.95 | -119.22 |
Free Cash Flow Per Share | 0.17 | 0.07 | 0.00 | -0.01 | 0.61 | -1.15 |
Dividend Per Share | - | 0.110 | 0.100 | 0.300 | 0.500 | 1.000 |
Dividend Growth | - | 10.00% | -66.67% | -40.00% | -50.00% | - |
Gross Margin | 34.09% | 35.46% | 32.15% | 31.40% | 33.38% | 27.91% |
Operating Margin | 16.39% | 18.14% | 14.43% | 14.46% | 17.42% | 13.21% |
Profit Margin | 8.37% | 9.88% | 11.19% | 14.90% | 15.10% | 14.08% |
Free Cash Flow Margin | 4.21% | 1.75% | 0.01% | -0.32% | 11.25% | -19.84% |
EBITDA | 156.36 | 167.29 | 147.77 | 153.9 | 172.16 | 153.98 |
EBITDA Margin | 38.26% | 38.77% | 36.03% | 33.12% | 30.77% | 25.62% |
D&A For EBITDA | 89.35 | 89.03 | 88.59 | 86.72 | 74.68 | 74.59 |
EBIT | 67 | 78.26 | 59.17 | 67.18 | 97.48 | 79.39 |
EBIT Margin | 16.39% | 18.14% | 14.43% | 14.46% | 17.42% | 13.21% |
Effective Tax Rate | 49.04% | 45.35% | 22.70% | 22.44% | 22.49% | 5.56% |
Advertising Expenses | - | 3.45 | 3.55 | 3.79 | 4.84 | 6.2 |